Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in japan: The Stroke Unit Multicenter Observational (SUMO) study

Stroke

Volumn 40, Issue 1, 2009, Pages 30-34

  Sato, Shoichiro ^a   Uehara, Toshiyuki ^a   Toyoda, Kazunori ^a   Yasui, Nobuyuki ^b   Hata, Takashi ^c   Ueda, Toshihiro ^c   Okada, Yasushi ^e   Toyota, Akihiro ^d   Hasegawa, Yasuhiro ^f   Naritomi, Hiroaki ^a   Minematsu, Kazuo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

^c Yokohama Stroke and Brain Center ^*  (Japan)

^d CHUGOKU ROSAI HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Stroke management; Stroke units; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; WARFARIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; JAPAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTHROMBIN TIME; BRAIN; BRAIN ARTERY; CAROTID ARTERY DISEASE; DRUG APPROVAL; DRUG EFFECT; ECHOGRAPHY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOLOGY; PROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VASCULARIZATION;

AGED; BRAIN; CAROTID ARTERY DISEASES; CEREBRAL ARTERIES; DRUG APPROVAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; JAPAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PROTHROMBIN TIME; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 60549096683     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.524942     Document Type: Article

References (16)

1. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42:976 -982.
2. Yamaguchi T, Hayakawa T, Kikuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993;3:269-272.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y. Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810 -1815.
5. Weimar C, Kraywinkel K, Maschke M, Diener HC; German Stroke Study Collaboration. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator. Cerebrovasc Dis. 2006;22:429-431.
6. Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172: 1307-1312.
7. Demaerschalk BM, Bobrow BJ, Paulsen M; Phoenix Operation Stroke Executive Committee on behalf of the Phoenix Metropolitan Matrix of Primary Stroke Centers. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience. Stroke. 2008;39:1246 -1253.
8. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). Stroke. 2005;36:1512-1518.
9. Demaerschalk BM, Durocher DL. How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers. Stroke. 2007;38:1309-1312.
10. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924 -928.
11. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomized trials of organized in-patient (stroke unit) care after stroke. BMJ. 1997;314:1151-1159.
12. Guideline Committee for intravenous rt-PA (alteplase) in acute ischemic stroke: guidelines for intravenous application of rt-PA (alteplase). Jpn J Stroke. 2005;26:327-354.
13. Shinohara Y, Yamaguchi T. Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke. 2008;3:55- 62.
14. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association; American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
15. Engelter ST, Gostynski M, Papa S, Ajdacic-Gross V, Lyrer PA. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis. 2007;23:211-215.
16. Shinohara Y. The changing face of the burden of stroke in Japan. Int J Stroke. 2007;2:133-135.